AMRX logo

Amneal Pharmaceuticals Inc. (AMRX)

$21.12

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AMRX

Market cap

$7.36B

EPS

0.41

P/E ratio

41.4

Price to sales

2.22

Dividend yield

--

Beta

1.248099

Price on AMRX

Previous close

$21.23

Today's open

$21.12

Day's range

$20.75 - $21.23

52 week range

$11.39 - $22.07

Profile about AMRX

CEO

Chirag Patel

Employees

8700

Headquarters

Bridgewater, NJ

Exchange

Nasdaq Global Select

Shares outstanding

348412726

Issue type

Common Stock

AMRX industries and sectors

Healthcare

Pharmaceuticals

News on AMRX

Amneal: Buy More After Impressive Q3 Results, As Active Drug Pipeline Keeps Growing

Amneal Pharmaceuticals gets a buy reaffirmed, despite its sharp rally, supported by a robust pipeline, niche demand, improving margins, and projected upside. Amneal delivered a fourth consecutive earnings beat, with Q3 revenue up 10% and higher FY26 revenue guidance. Kashiv integration and biosimilars offer growth potential, while positive operating cash flow and an improving operating margin support earnings quality.

news source

Seeking Alpha • Nov 17, 2026

news preview

Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®

BRIDGEWATER, N.J., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the European Commission (EC) has granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.

news source

GlobeNewsWire • a day ago

news preview

Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers

BRIDGEWATER, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been named a BioSpace 2027 Best Place to Work, earning the No.1 ranking among large employers in the life sciences industry.

news source

GlobeNewsWire • Nov 10, 2026

news preview

AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance Raised

Amneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.

news source

Zacks Investment Research • Nov 4, 2026

news preview

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

Amneal Pharmaceuticals NASDAQ: AMRX reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earnings per share increased 53% to $0.26.

news source

MarketBeat • Nov 3, 2026

news preview

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Amneal Reports Third Quarter 2026 Financial Results

–  Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance –

news source

GlobeNewsWire • Nov 3, 2026

news preview

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.17 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Amneal Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Amneal Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AMRX on M1